Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
  • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
  • C07K2317/622—Single chain antibody (scFv)

Definitions

• scFvs therapeutic bispecific scFv conjugates in which a mutated human serum albumin linker is covalently bonded to distinct amino and carboxy terminal single- chain Fv molecules
• Antibody-like binding moieties are often used for therapeutic applications.
• Antibody fragments such as scFvs generally exhibit shorter serum half lives than intact antibodies, and in some therapeutic applications increased in vivo half lives would be desirable for therapeutic agents possessing the functionality of such fragments / scFvs.
• Human serum albumin is a protein of about 66,500 kD and is comprised of 585 amino acids including at least 17 disulphide bridges. As with many of the members of the albumin family, human serum albumin plays an important role in human physiology and is located in virtually every human tissue and bodily secretion. HSA has the ability to bind and transport a wide spectrum of ligands throughout the circulatory system, including the long-chain fatty acids, which are otherwise insoluble in circulating plasma.
• MM-1 1 1 A bispecific scFv HSA conjugate designated MM-1 1 1 (also referred to as B2B3-1) is described in copending US patent application 12/757,801 , and PCT publication number WO2009/126920, each of which is incorporated herein by reference in its entirety.
• MM-1 1 1 is currently undergoing clinical trials, including an open-label Phase 1-2 and pharmacologic study of MM-1 1 1 in patients with advanced, refractory HER2 positive cancers, and an open-label Phase 1-2 trial of MM-11 1 in combination with trastuzumab (HERCEPTIN) in patients with advanced HER2 positive breast cancer.
• HERCEPTIN trastuzumab
• ErbB2/ErbB3 (ErbB2/3) oncogenic heterodimer is the most potent ErbB receptor pairing with respect to strength of interaction, impact on receptor tyrosine phosphorylation, and effects on downstream signaling through mitogen activated protein kinase and phosphoinositide-3 kinase pathways.
• ErbB3 signaling has become recognized as an important mechanism of resistance to ErbB2 (HER-2) targeted agents (such as trastuzumab) in clinical use.
• HER-2 ErbB2
• Current ErbB2-targeted therapies do not effectively inhibit heregulin activated ErbB2/3.
• Preclinically combinations of MM-1 1 1 inhibiting heregulin activation of ErbB2/3 without blocking ErbB2) with trastuzumab (targeting ErbB2) provide complete inhibition.
• MM-1 1 1 specifically targets the ErbB2/ErbB3 heterodimer and abrogates ligand binding. In preclinical models of HER-2+ gastric, breast, ovarian and lung cancers, MM-1 1 1 inhibits ligand-induced ErbB3 phosphorylation, cell cycle progression, and tumor growth. SUMMARY OF THE INVENTION
• MM-111 (B2B3-1).
• MM- 111 is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1.
• MM-111 comprises first and second binding moieties that are single-chain Fv molecules: the first binding moiety specifically binds ErbB3 and the second binding moiety specifically binds ErbB2.
• Dosage units comprising fixed amounts of MM-111 are also provided.
• bispecific scFv conjugates such as MM-111 are administered at at least weekly intervals (e.g., weekly or biweekly) at a dose of at least 20 mg/kg.
• an initial loading dose that is equal to or greater than 120% of the weekly or biweekly dose is administered at the onset of therapeutic treatment with the bispecific scFv conjugate.
• Figure 1 shows MM-1 11 serum concentration levels obtained in patients treated with 3, 6, 12, or 20 mg/kg of MM-11 1.
• a preclinical PK/PD model relating [drug] to tumor growth inhibition was used to select the EC80 as a target clinical trough level (Cmin).
• a clinical population-PK model indicates that a 20 mg/kg maintenance dose reaches or exceeds this target in 80% of the patients by week 3 of treatment.
• a loading dose of 25 mg/kg is predicted to achieve the target in week 1.
• X Axis Serum concentration (mg/L).
• Y axis Weeks 0, 2, 4, and 6.
• Figure 2 shows a clinical trial enrollment and response summary.
• MM-1 1 Provided are methods of administering MM-1 1 1.
• a first method for the treatment of a human patient diagnosed with cancer characterized by expression of ErbB2 receptor comprising administering an effective amount MM-11 1 to the patient at an interval measured in days, the method comprising: administering to the patient a single loading dose of at least 20 mg/kg of MM-1 1 1 followed at at least seven day intervals by at least one administration of a single maintenance dose of MM-11 1, wherein the maintenance dose is smaller than the loading dose.
• the preceding method is one wherein the maintenance dose is at least 5 mg/kg less than the loading dose.
• the preceding methods are methods wherein the at least seven day intervals are intervals of every 10 days.
• preceding methods are methods wherein the at least seven day intervals are intervals of every 14 days. In other aspects the preceding methods are methods wherein the at least seven day intervals are intervals of every 18 days. In other aspects the preceding methods are methods wherein the at least seven day intervals are intervals of every 21 days.
• the first method is one wherein the at least seven day intervals are intervals of a number of days indicated by a top number, the loading dose of at least 20 mg/kg of MM-1 11 is a dose in mg/kg indicated by a middle number, and the maintenance dose of MM- 111 smaller than the loading dose is a dose in mg/kg indicated by a bottom number in a cell of Table 1C selected from any populated cell of Table 1C.
• a second method for the treatment of a human patient diagnosed with cancer characterized by expression of ErbB2 receptor, comprising administering an effective amount MM-111 to the patient, the method comprising: administering to the patient a single initial dose of at least 15 mg/kg of MM-1 11 followed at at least seven day intervals by at least one administration of a subsequent dose of MM-111 which is the same as the initial dose.
• the preceding second method is one wherein the dose is about 20 mg/kg. In other aspects the preceding second method is one wherein the dose is about 30 mg/kg. In other aspects the preceding second method is one wherein the dose is about 44 mg/kg. In other aspects the preceding second method is one wherein the dose is about 75 mg/kg. In other aspects the preceding second method is one wherein the dose is about 105 mg kg.
• the second method is one wherein the at least seven day intervals are intervals of a number of days indicated by a top number and the dose of at least 15 mg/kg of MM-1 1 1 is a dose in mg/kg indicated by a bottom number in a cell of Table 1C selected from any populated cell of Table 1C.
• composition A for use in the treatment of a human patient diagnosed with cancer characterized by expression of ErbB2 receptor, said composition comprising MM-1 1 1 for administration to the patient at an interval measured in days, as a single loading dose of at least 20 mg/kg of MM-1 11 followed at at least seven day intervals by at least one administration of a single maintenance dose of MM- 1 11 , wherein the maintenance dose is smaller than the loading dose.
• a composition B is provided which is composition A wherein the maintenance dose is at least 5 mg/kg less than the loading dose.
• composition A or composition B is one wherein the at least seven day intervals are intervals of every 10 days.
• composition A or composition B is one wherein the at least seven day intervals are intervals of every 14 days.
• composition A or composition B is one wherein the at least seven day intervals are intervals of every 18 days. In certain aspects composition A or composition B is one wherein the at least seven day intervals are intervals of every 21 days.
• composition A is a composition wherein the at least seven day intervals are intervals of a number of days indicated by a top number, the loading dose of at least 20 mg/kg of MM-111 is a dose in mg/kg indicated by a middle number, and the maintenance dose of MM- 111 smaller than the loading dose is a dose in mg/kg indicated by a bottom number in a cell of Table 1C selected from any populated cell of Table 1C.
• a composition C for use in the treatment of a human patient diagnosed with cancer characterized by expression of ErbB2 receptor, said composition comprising MM-1 11 for administration to the patient at an interval measured in days as a single initial dose of at least 15 mg/kg of MM-11 1 followed at at least seven day intervals by at least one administration of a subsequent dose of MM-1 11 which is the same as the initial dose.
• the dose is about 20 mg/kg.
• the dose is about 30 mg/kg.
• the dose is about 44 mg/kg.
• the dose is about 75 mg/kg.
• the dose is about 105 mg/kg.
• composition C the at least seven day intervals are intervals of a number of days indicated by a top number and the dose of at least 15 mg/kg of MM-1 11 is a dose in mg/kg indicated by a bottom number in a cell of Table 1C selected from any populated cell of Table 1C. Kits and Unit Dosage Forms
• kits that include a pharmaceutical composition containing MM-111 including a pharmaceutically-acceptable carrier, in a therapeutically effective amount adapted for use in the preceding methods.
• the kits include instructions to allow a practitioner (e.g., a physician, nurse, or patient) to administer the composition contained therein to treat an ErbB2 expressing cancer.
• kits include multiple packages of the single-dose pharmaceutical composition(s) containing an effective amount of MM-1 1 1 for a single administration in accordance with the methods provided above.
• instruments or devices necessary for administering the pharmaceutical composition(s) may be included in the kits.
• a kit may provide one or more pre-filled syringes containing an amount of MM-1 11 that is about 100 times the dose in mg/kg indicated for administration in the above methods.
• Such unit dosage forms preferably contain about 2g, about 3g, about 4.4g, about 7.5g or about 10.5g.
• kits may also include additional components such as instructions or administration schedules for a patient suffering from a disease or condition (e.g., a cancer, autoimmune disease, or cardiovascular disease) to use the pharmaceutical compositions) containing an bispecific scFv, or any binding, diagnostic, and/or therapeutic agent conjugated thereto.
• a disease or condition e.g., a cancer, autoimmune disease, or cardiovascular disease
• additional components such as instructions or administration schedules for a patient suffering from a disease or condition (e.g., a cancer, autoimmune disease, or cardiovascular disease) to use the pharmaceutical compositions) containing an bispecific scFv, or any binding, diagnostic, and/or therapeutic agent conjugated thereto.
• Example 1 Mode of Administration of MM-111
• MM-111 is prepared as a formulation containing 25 mg/ml MM-1 11 in a sterile aqueous solution comprising 20 mM L-histidine hydrochloride, 150 mM sodium chloride, pH 6.5, which is stored at 2-8°C.
• MM-1 1 1 must be brought to room temperature prior to administration.
• Containers e.g., vials
• MM-111 must not be shaken.
• the appropriate quantity of MM-11 1 is removed from the container, diluted in 250 mL of 0.9% normal saline and administered as an infusion using a low protein binding in-line filter (preferably a 0.22 micrometer filter).
• MM-11 1 is initially administered over about 90 minutes (first administration). In the absence of an infusion reaction, subsequent doses are administered over about 60 minutes.
• a patient's body weight at the start of a dosing cycle is to be used to calculate the dose used throughout the cycle. Should a patient's body weight change by more than 10%, a new total dose is calculated to reflect this change.
• Example 2 Dosage and Administration of MM-111
• Preferred plasma concentrations of MM1 1 1 achieved during treatment are at least 106 mg/L. It has now been discovered that certain combinations of dose frequency and dosage will achieve and maintain this plasma concentration during the course of treatment in at least half, and preferably in more than 60%, 70% or 80% of treated patients.
• a higher initial dose (loading dose - LD) is given, followed as defined intervals by at least one maintenance dose (MD).
• Intervals of dosing in days are typically indicated as QxD, wherein x represents an integer, so that a QxD of 7 indicates dosing every 7 days.
• Table 1A, Table IB, and Table 1C below show doses and dosing intervals of the invention.
• the indicated loading doses are optional - initial doses are preferably made at the indicated loading dose (LD), but may (e.g., as directed or at the physician's discretion) be made at the maintenance dose (MD).
• Table 1 A provides a set of exemplary dosing intervals, loading doses and maintenance doses.
• Table IB provides a variation of Table 1A allowing for dosage variability (indicated as "about”) of up to +/- 3 mg/mL.
• Table 1C appears below and provides a more extensive set of exemplary dosing intervals, loading doses and maintenance doses.
• the top figure is the integer x in the interval QxD (e.g., 18 as the top figure in a cell indicates a dosing interval of Q18D or every 18 days)
• the middle figure represents the (optional) loading dose (LD) in mg/kg
• the bottom figure represents the maintenance dose (MD) in mg/kg.
• the top cell in Table 1 A indicates a dosing interval (QxD) of once every seven days, a loading dose
• a first-in-human phase 1-2 study evaluates the safety and tolerability of MM-11 1 and preliminarily explores efficacy in HER-2+ advanced breast cancer (ABC).
• the safety data obtained during the Phase 1 dose escalation portion of this study provide the basis of this report.
• Phase 1 Patients (pts) with histologically confirmed HER-2+ advanced solid tumors progressing or recurring on standard therapy; aged > 18 years; ECOG PS ⁇ 2 and adequate organ function were eligible for Phase I. Pts with stable CNS lesions were also eligible. A Modified Fibonacci schema was used for dose escalation in Phase I. Primary endpoints for Phase 1 were
• Phase 1 To determine the Phase 2 dose based upon either the maximum tolerated dose (MTD) or the maximum feasible dose with HER2 -positive solid tumors.
• Phase 2 To estimate Progression-Free Survival (PFS) in patients with HER2-positive breast cancer progressing on trastuzumab and/or lapatinib
• MTD defined as highest dose level in which a DLT is experienced by ⁇ 2 patients in a cohort
• Example 6 Administration of MM-111 at greater than weekly intervals

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Oncology (AREA)
• Immunology (AREA)
• Biophysics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=46207797

Family Applications (1)

Country Status (6)

Cited By (6)

Families Citing this family (6)

Family Cites Families (2)

• 2011
  • 2011-12-12 US US13/992,460 patent/US20140017264A1/en not_active Abandoned
  • 2011-12-12 JP JP2013543410A patent/JP2014500278A/ja not_active Withdrawn
  • 2011-12-12 CA CA2819554A patent/CA2819554A1/en not_active Abandoned
  • 2011-12-12 WO PCT/US2011/064496 patent/WO2012079093A2/en not_active Ceased
  • 2011-12-12 AU AU2011341337A patent/AU2011341337A1/en not_active Abandoned
  • 2011-12-12 EP EP11847515.1A patent/EP2648753A4/en not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events